Learn more about WIPO Re:Search members by viewing their detailed profiles.
WIPO Re:Search Resource Platform terms and conditions of use
Re:Search Institution Members
Export data
Choose one option to export the data.
PPT
161 Results for Members
Members
Housed at the Nathan Campus of Griffith University in Brisbane, Australia, the Griffith Institute for Drug...
Founded in 1993, the Infectious Disease Research Institute (IDRI) is focused on developing products that solve...
Surrounded by the delicate ecosystems of the Wet Tropics and the Great Barrier Reef, James Cook University...
Between 2015 and 2016, McGill University and its affiliated hospitals were awarded $473 million in research...
McMaster University is a public research univerity, with its Michael G. DeGroote Institute for Infectious...
The mission of the Massachusetts Institute of Technology (MIT) is to advance knowledge and educate students in...
168 Results for Collaborations
Collaborations
Dr. Hu developed a dipstick diagnostic for S. japonicum, a species of the parasitic flatworm commonly found in the Far East. BVGH connected Dr. Hu with Dr. Alexander Odaibo at the University of Ibadan, who used samples from Schistosoma-infected patients to assess the dipstick’s ability to detect S. mansoni and S. haematobium, the prevailing species in Africa.
Dr. Demanou, Head of the Arbovirus and Hemorrhagic Fever Virus Laboratory at CPC, believed that dengue fever was underestimated in Cameroon, and was interested in determining the causes and prevalence of non-malarial fevers in the country. BVGH connected Dr. Demanou with Dr. Pinsky, who had developed an RT-PCR diagnostic capable of distinguishing between febrile illnesses. Dr. Demanou provided Dr. Pinsky with over 200 plasma and serum samples from Cameroonian febrile patients, which Dr. Pinsky screened using his multiplexed assay. The results indicated that a large proportion of malaria cases were missed by conventional testing, results that could potentially inform diagnostic development for febrile cases in Cameroon.
Dr. Oyibo was interested in determining which infectious agents (besides malaria) caused febrile illnesses in patients of Lagos state. BVGH connected Dr. Oyibo with Dr. Pinsky, who had developed a highly sensitive real-time RT-PCR-based molecular diagnostic platform that detected and distinguished nucleic acids from dengue virus and Plasmodium parasites. BVGH facilitated the placement of a graduate student from Dr. Oyibo’s laboratory in Dr. Pinsky’s laboratory at Stanford to advance her education and training. Using the multiplex assay to screen Dr. Oyibo’s plasma and whole blood samples from patients with malarial and non-malarial fevers, the student confirmed malaria diagnoses in a significant number of samples that had tested negative by microscopy.
Drs. Pluschke and Scherr at the Swiss TPH were interested in repurposing tuberculosis drugs to treat Buruli ulcer, a bacterial infection caused by Mycobacterium ulcerans. BVGH connected Drs. Pluschke and Scherr with Drs. Thompson and Ramon-Garcia at UBC, who had discovered that certain avermectins showed promising activity against M. tuberculosis and other mycobacterial species. The UBC investigators shared eight avermectins with Drs. Pluschke and Scherr, who tested the compounds for their activity in an in vitro screen against clinical isolates of M. ulcerans.
Drs. Izurieta developed a solar-chemical toilet that sanitizes waste products. To determine the efficacy, he needed to assess the viability of parasite eggs in soil and sewage samples post-sanitization. To assist Dr. Izurieta and his colleague Dr. Reina Ortiz, BVGH connected them with Dr. Selvaganapathy, a biomicrofluidics expert. With support from the USF investigators, Dr. Selvaganapathy developed a tangential flow filtration device and tested the efficacy of the device in concentrating Ascaris eggs.
Dr. Kaushansky was interested in accessing a class of compounds targeting a specific host protein, as she had previously shown that activating this protein might be an effective therapeutic strategy against liver-stage malaria. BVGH connected Dr. Kaushansky with Pfizer, who provided a novel activator compound to support her antimalarial drug discovery efforts.
170 Results for Assets
Assets
WRAIR has developed and patented a novel hybrid molecule containing both Type 1 VK210 and Type 2 VK247 P. vivax repeats. This molecule VMP001 induces a potent immune response to both Type 1 and Type 2 sporozoites in animal models. In addition to the repeat region, the recombinant molecule contains the N- and C-terminal regions of CS protein including several T and B cell epitopes.
CelTOS (also known as Ag2) is a highly conserved antigen that is expressed in malaria preerythrocytic sporozoites and sexual stage ookinetes; in addition, it is involved in sporozoite invasion of hepatocytes. WRAIR has developed and patented a His-tagged recombinant protein of full length CelTOS from both P. berghei and P. falciparum.
A method for the quantitation of small molecules from dried blood spots to accurately measure single nanogram/mL amounts of material from 15 microL of dried blood or plasma. Dried blood spots can be stored and shipped easily, facilitating measurements in conjunction with drug compliance studies or clinical trials conducted in austere environments where the collection, separation, and shipment of frozen plasma is not logistically feasible.
WRAIR has an established Veterinary Medicine Facility that offers collaborations for preclinical studies with non-human primates and other animals. WRAIR has a Nonhuman Primate Specific Pathogen Free Colony of Indian Origin Rhesus Macaques available for collaborative studies in tropical disease research, testing vaccines and therapeutics for malaria, leishmaniasis and dengue fever.
A new vaccination strategy for dengue virus (DENV) was evaluated in rhesus macaques by priming with tetravalent purified inactivated virus (TPIV) which is a WRAIR vaccine or tetravalent plasmid DNA vaccines expressing the structural prME gene region (TDNA) then boosting 2 months later with a tetravalent live attenuated virus (TLAV) vaccine. Both vaccine combinations elicited virus neutralizing (N) antibodies. The TPIV/TLAV combination afforded complete protection against DENV 3 challenge at month 8. In a second experiment, priming with TPIV elicited N antibodies against all four serotypes (GMT 1:28 to 1:43). Boosting with TLAV led to an increase in the GMT for each serotype (1:500 to 1:1200 for DENVs 1, 3, and 4, and greater than 1:6000 for DENV 2), which declined by month 8 (GMT 1:62 for DENV 3, 1:154 for DENV 1, 1:174 for DENV 4, and 1:767 for DENV 2). After challenge with each one of the four DENV serotypes, vaccinated animals exhibited no viremia but showed anamnestic antibody responses to the challenge viruses. Currently, WRAIR is involved in conducting early stage clinical trials on the Tetravalent Purified-Inactivated Virus (TPIV) Vaccine for Dengue.
The Clinical Trials Center (CTC) was established as a clinical research unit in 1992 to support military, Federal, and industrial partners in their mission to develop new vaccines, drugs, and diagnostic systems that will benefit not only the military, but all people. An average of 13-15 clinical studies are conducted each year through the CTC. To implement these studies, the CTC recruits over 350 human volunteers per year. Services: Design and implementation of Phase I, II, and III clinical protocols; Consultative support in all aspects of study design; Recruitment and management of study volunteers; Design and maintenance of clinical records, case report forms and databases; On-site storage and monitoring of study vaccines and medication; Outpatient facilities with full clinical support staff for study visits; Quality Assurance WRAIR also provides regulatory services: Development of regulatory strategies for new product submissions, preparation of regulatory documents and their submission to the FDA.